BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer

Gary Middleton, Yiqun Yang, Catarina D Campbell, Thierry André, Chloe E Atreya, Jan H M Schellens, Takayuki Yoshino, Johanna C Bendell, Antoine Hollebecque, Autumn J McRee, Salvatore Siena, Michael S Gordon, Josep Tabernero, Rona Yaeger, Peter J O'Dwyer, Filip De Vos, Eric Van Cutsem, John M Millholland, Jan C Brase, Fatima RangwalaEduard Gasal, Ryan B Corcoran

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)
155 Downloads (Pure)

Fingerprint

Dive into the research topics of 'BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences